BioSpace News Archive

PDUFA Target Action Date for INVELTYS™ is August 24, 2018

Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018

ValGenesis, Inc. is pleased to announce that a global Life Science company with integrated services and product offering has chosen ValGenesis Validation Lifecycle Management System to manage their corporate validation lifecycle process in a 100% paperless mode.

Fibrocell Science, Inc. reported financial results for the second quarter ended June 30, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.

Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Expected to Initiate in the Second Half of 2018

VolitionRx Limited announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition’s proprietary Nu.Q™ platform technology

Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

An experienced multidisciplinary team joins Pacific Neuroscience Institute to treat psychiatric and neurological conditions including Alzheimer’s disease, depression and anxiety, and to promote healthy brain aging.

Revenue increases 102% to $5.2 million. Net income of $1.0 million achieved

New CTO Kyle Ryan from Intuit and VP of Product Andrea Kowalski from athenahealth bring extensive experience building scalable cloud-based platforms and market-leading healthcare clinical and business management solutions